Moderna battles Pfizer/Biontech to generate the first pivotal study data for a Covid-19 vaccine.
As the company is punished for its failure to diversify, could it be forced into making an acquisition?
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
More details on an adverse event in a trial of Astrazeneca's AZD1222 will be needed to assess the fallout for other vaccine developers.